Vanda Pharmaceuticals Inc.
VNDA
$3.87
-$0.05-1.28%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -611.38% | -104.67% | -3,986.13% | -397.24% | -227.49% |
Total Depreciation and Amortization | -10.84% | 70.38% | 239.14% | 226.91% | 231.94% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -248.11% | 107.61% | -139.46% | -93.26% | -56.98% |
Change in Net Operating Assets | -127.43% | -74.54% | -42.22% | 75.50% | -68.34% |
Cash from Operations | -537.93% | 51.31% | -611.27% | 47.59% | -76.20% |
Capital Expenditure | 83.92% | 99.79% | -570.83% | -2,867.27% | -5,217.65% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 385.94% | -92.64% | -65.44% | 92.86% | -108.28% |
Cash from Investing | 340.98% | 109.12% | -65.87% | 92.00% | -109.73% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -- | -- | -- | -- | -- |
Foreign Exchange rate Adjustments | 450.00% | -234.67% | 155.74% | 42.31% | -131.11% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 188.91% | 103.84% | -107.41% | 89.12% | -104.87% |